NCT02765243View on ClinicalTrials.gov

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

January 12, 2019

Study Completion Date

December 30, 2023

Conditions
NeuroblastomaEffects of Immunotherapy
Interventions
BIOLOGICAL

Anti-GD2 CART

Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells

Trial Locations (1)

510282

Zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER

NCT02765243 - Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma | Biotech Hunter | Biotech Hunter